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Gene expression proﬁling by cDNA array analysis in melanoma is hampered by the need for large amounts of RNA
to prepare reliable probes for array hybridization. On the other hand, for ex vivo analysis of malignant cells from
melanocytic tumors laser pressure catapulting is an essential prerequisite to obtain noncontaminated melanocytic
preparations; however, laser pressure catapulting prepared material provides only nanogram amounts of RNA. In
this study we present an approach to overcome these limitations by combining laser pressure catapulting and real-
time polymerase chain reaction based SMART cDNA ampliﬁcation technology. Reproducible and reliable
hybridization patterns from about 500 laser pressure catapulting prepared cell equivalents from 22 cases of
melanocytic tumors were generated using array analysis. Univariate analysis revealed signiﬁcant differences of the
expression pattern of melanocytic nevi, melanomas, and melanoma metastases. Multivariate analysis with four
genes being the best univariate discriminative features (tyrosinase related protein 2, translation initiation factor 2c,
ubiquitine conjugating enzyme E2I and one expressed sequence tag) allowed clustering of nevi, melanomas, and
melanoma metastases with an accuracy of 82%. Data validation was performed by additional quantitative reverse
transcription–polymerase chain reaction (TaqMan–reverse transcription–polymerase chain reaction). Taken
together, this study shows, that (1) array analysis is feasible on tumors with rather low cell numbers, and (2)
differences in expression proﬁles allow discrimination between benign and malignant lesions. Expression patterns
of marker genes deﬁned in unequivocal histopathologic entities may improve the diagnostic and prognostic
assessment of difﬁcult melanocytic lesions, which is still the hardest problem in dermatopathology.
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The discrimination between benign and malignant melano-
cytic lesions is often conjectural. Furthermore, if a lesion is
diagnosed as melanoma, it would be highly desirable to
supplement the pathology with molecular markers discri-
minating potentially metastatic and nonmetastatic biologic
phenotypes more precisely. Molecular markers, which were
previously used (e.g., p53, Ki67, cathepsins, collagenase,
c-fos, c-myc) have some prognostic value but due to
conjectural results none of those has made it into clini-
cal routine (Vogt et al, 1997). Therefore, establishing
a technique enabling the analysis of multiple parameters
simultaneously is crucial in order to expand the knowledge
on known potential markers and add new ones.
The development of melanoma is a process, in which the
cellular homeostasis is dramatically changed by the dereg-
ulation of the expression of many genes (Herlyn et al, 2001).
These complex changes can now be analyzed by genome-
wide profiling techniques, such as the cDNA array hybridi-
zation for generating the desired marker profiles. Cancer
research, however, in this specific entity and in others with
small amounts of tumor cells was hitherto hampered by the
excessive amounts of RNA necessary to produce reliable
probes for array hybridization (Bertucci et al, 1999). There-
fore, the majority of tumors analyzed by array or chip
analyses were either metastases (Bittner et al, 2000) or
tumor entities, which harbor enough tumor tissue for
purification of sufficient amounts of RNA (Alizadeh et al,
2000; Dhanasekaran et al, 2001; Young et al, 2001; Ahr et al,
2002). Alternatively, cells from fresh tumor biopsies were
taken in culture for several passages before preparing RNA
from these cultured cells (Bittner et al, 2000; Brem et al,
2001), but the molecular ‘‘proximity’’ to the original tumor is
questionable.
The tumor cells in nevi or early melanomas may
constitute only a minor fraction of the total tissue volume
excised during surgery. Isolation of the melanocytic cells
from small early lesions by conventional microdissection
techniques might include variable numbers of contaminat-
ing nonmelanoma cells. The Laser Pressure Catapulting
(LPC) microscope allows to isolate directly and analyze
small cell populations of interest virtually without any
contaminating cells directly from hematoxylin and eosin
stained histologic sections (Bohm et al, 1997; Schutze and
Lahr, 1998; Westphal et al, 2002). As only low amounts of
RNA can be gained from LPC prepared cells, amplification
of the RNA is a prerequisite for array analysis. Methods
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involving RNA amplification based on T7-primed in vitro
transcription were shown to generate reliable results in
studies of neuronal cells and early colorectal carcinomas
(Luo et al, 1999; Kitahara et al, 2001). The procedures
involved, however, are rather time-consuming and expen-
sive and may therefore be not applicable for routine
purposes. We have recently shown a fast and inexpensive
polymerase chain reaction (PCR)-based alternative ap-
proach that seems to be much more suitable for routine
applications (Becker et al, 2001) and applied this technique
to RNA from LPC-prepared melanocytic cells.
Results
Reproducibility of array hybridization experiments
coupled to LPC and SMART To demonstrate the reprodu-
cibility of our method, we performed the analysis of four
of our cases as independent duplicate experiments (case
nos 2, 9, 18, and 21; Table I). A typical result of one of
the experiments is shown in Fig 1(b). For the pairwise
comparison an expression threshold for a significant signal
intensity was set as described (e.g., no. 2068-1 and no.
2068-2, Fig 1b: yellow lines). Genes below these thresholds
are not taken into account because of an increased
probability of giving false positive results because of low
signal-to-background ratios (Fig 1b: yellow spots); 2.2% of
the detected genes appeared as ‘‘regulated’’. These genes
represent false positives (Fig 1b: blue spots above the
red line and below the green line). The remaining signals
(97.8%, 270 of 4467 genes displayed on the array) are
evenly expressed in this duplicate experiment (Fig 1b: blue
spots between the red and the green lines). The average
rate of false positive regulated genes in four independent
experiments was 6.9% (2.2% of 270 genes, 2.2% of 410,
10.3% of 77, and 13% of 84).
Observed categories of regulation during progression
of melanocytic lesions For assessment of the proportions
and sizes of classes of regulated genes during melanoma
progression, all regulated genes were clustered into four
regulative categories according to the pattern of regulation
during progression from nevi versus melanoma versus
melanoma metastases as described above. These major
regulative categories were further split with regard to their
functional context, based on the recent knowledge in the
literature: (1) metabolism; (2) signaling/cell cycle; (3)
receptors/attachment; (4) others with known function; and
(5) unknown function. The absolute number of genes
regulated in the different functional clusters are summarized
in Fig 2. As expected, the most prominent differences in
gene expression profiles of known genes was observed
in the category ‘‘metabolism’’ showing upregulation in
melanomas versus nevi (Fig 2, light gray). The average
expression ratios of the genes included in the analysis and
their categories are summarized in a detailed table, which is
available as supplemental material.
Classiﬁcation of nevi, melanomas, and melanoma
metastases We analyzed the melanocytic tumors listed in
Table I by array analysis. From 4467 spotted genes, 232
passed the filter an expression threshold of 5%, averaged
over all cases. Univariate analysis revealed those genes that
were statistically significantly regulated in different stages
of progression. The genes with the highest F-values from
Table I. Melanocytic lesions included in this study
Case no.
Histopathologic
diagnosis Clark level
Tumor
thickness
(mm)
1 Melanocytic nevus
2 Dermal nevus
3 Dermal nevus
4 Compound nevus
5 Melanocytic nevus
with lymph. infiltration
6 Melanocytic nevus with
lymph. infiltration
7 Melanocytic nevus with
lymph. infiltration
8 Compound nevus
9 NMM III 0.8
10 NMM III 0.8
11 SSM II 0.25
12 NMM IV 2.3
13 SSM II 0.2
14 SSM IV 0.8
15 SSM, secondary NMM IV 1.8
16 SSM III 1
17 SSM III 1.05
18 Metastasis amelanotic
19 Metastasis amelanotic
20 Metastasis
21 Metastasis melanotic
22 Metastasis melanotic
23 Melanocytic nevus
24 Melanocytic nevus
25 Melanocytic nevus
26 NMM V 18
27 NMM V 8
28 NMM V 4.7
29 LMM V 5
30 LMM V 7.5
31 Metastasis amelanotic
32 Metastasis amelanotic
33 Metastasis melanotic
34 Metastasis amelanotic
35 Metastasis amelanotic
Case nos 1 to 22 were used for array analysis; case nos 23 to 35 were
used as further validation set for reverse transcription–PCR. SSM,
superficial spreading melanoma; NMM, nodular melanoma; LMM, lentigo
maligna melanoma.
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Figure 1
(a) A typical protocol during SMART cDNA
amplification PCR with two different tem-
plates recorded with the Rotor-Gene real-
time PCR machine. The marks A and B label
the number of cycles used for equal amplifica-
tion of the templates; 22 and 25 cycles,
respectively. RT represents the control reac-
tion without reverse transcriptase during the
first-strand synthesis step in the SMART pro-
tocol. The inset shows an agarose gel with the
cDNA isolated from template A after 22 cycles
and template B after 25 cycles; on the lane
labeled RT the negative control is shown.
Equal volumes from the cDNA and the negative
control were loaded on each lane. M: DNA size
marker (sizes given in kb). (b) Array comparison
dotplot of two arrays hybridized with probes
generated from two independent LPC prepara-
tions from sections on two slides of the same
biopsy (no. 2068). After data analysis with AIDA
matrix the pairwise comparison of the normal-
ized expression data was performed by the
AIDA compare module. The detection thresh-
old was set to 16% and 15% for no. 2068-1
and 2068-2, respectively. The green and red
line represents 3-fold downregulation or upre-
gulation, respectively.
Figure 2
Numbers of genes regulated during
progression of melanocytic lesions
clustered according to functional
groups. Sorted according to the pattern
of regulation: (1) induction from nevi
towards melanoma (light gray); (2) in-
duction from melanoma towards metas-
tases (gray); (3) induction from nevi
towards melanoma and further upre-
gulation towards metastases (dark
gray); (4) genes upregulated from nevi
towards melanoma and subsequently
suppressed in metastases (black). The
groups contain the following gene func-
tions: Metabolism, signaling/cell cycle,
receptors/attachment, others, unknown
function.
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univariate analysis are listed in Table II sorted according to
their statistical relevance. Multivariate stepwise analysis of
the cases using those four most significant univariate
variables allowed classification of 82% of all cases correctly
in accordance to the expert histopathologic diagnosis
(Table IIIA). The resulting clusters of lesions are displayed
by plotting the canonical discriminant functions for each
case in Fig 3. This plot visualizes the relative distances of
the profiles using this set of four most discriminative
variables. For those four genes the average expression
value within each class of melanocytic lesion was calcu-
lated (Table II).
To verify the array data classification results, we analyzed
the expression of the marker genes shown in Table II by
quantitative real-time reverse transcription–PCR using Taq-
Man probes. In addition to the genes used for classification,
we included in this analysis a further eight genes that
reached the highest F-values in the univariate analysis. In
order to assure, that the markers are valid independent of
the set of lesions selected, the expression was analyzed in
another set of melanocytic lesions (three nevi, five melano-
mas, and five melanoma metastases, Table I: case nos
23–35). The expression values were normalized to GAPDH
expression. The normalized expression levels of three
genes (eIF2g, UBE2I, and the EST) were analyzed statisti-
cally by the same canonical discriminant analysis as used
for the array data. According to the histopathologic
diagnosis 85% of all cases could be classified correctly
(Table IIIB). The comparison of the expression values
obtained by reverse transcription–PCR with the regulation
observed in array analysis verifies the mode of regulation
from benign towards malignant lesions in nine of 12 genes
(Table IV).
Discussion
Gene expression profiles of melanoma cells were so far
restricted to advanced tumors harboring microgram
amounts of RNA or which were taken into culture from the
tumors and passaged several times to get enough cells
for RNA isolation (Bittner et al, 2000; Brem et al, 2001).
In contrast to the analysis of primary tumor material, the
analysis of cultured tumor cells might bear misleading
results due to adaptive effects under cell culture conditions.
The LPC-microdissection real-time SMART–PCR approach
presented herein, overcomes these limitations. We demon-
strate that with this approach gene expression analysis of
melanocytic cells isolated directly from routinely excised
biopsy material is fast and reasonably inexpensive.
By statistical analysis of the expression profiles of
melanocytic lesions we obtained a set of potential markers
(Table II), which discriminates melanocytic tumors of dif-
ferent levels of malignancy with an accuracy of 82%, if
compared with histopathology evaluation (Table III, Fig 3).
The few falsely classified lesions might represent certain
subsets of biologic phenotypes characterized by gene
expression changes outside of the typical range, which
are not recognizable by histopathology. This set of marker
genes could be further validated by quantitative reverse
transcription–PCR on a second set of melanocytic tumors,
reaching the same accuracy of 85% correctly classified
cases (Table III), although for statistical significance reasons
only three variables were included in the canonical
discriminant analysis. In addition, we analyzed a further
eight genes with the highest F-values from the univariate
analysis in the same set of lesions by reverse transcription–
PCR to validate the array results more stringently. Nine of 12
genes could be confirmed (Table IV). This result is even
more convincing, as the analyses were performed in two
different sets of melanocytic lesions.
The small amounts of RNA that are available from laser-
microdissected cells require a preamplification before
generating a probe for array hybridization. Recently, we
could demonstrate that SMART amplification of RNA is a
fast method for preparing reliable probes for cDNA array
analysis (Becker et al, 2001). This result is in good
agreement with experiments from other groups (Gonzalez
et al, 1999; Spirin et al, 1999; Vernon et al, 2000).
Leethanakul et al (2000) and Fink et al (2002) applied this
technique to material that was laser microdissected. We
enhanced the previously published protocols by applying a
real-time PCR-based amplification of the RNA. This way, we
could directly monitor the quantity of the cDNA synthesized
during the PCR process. In addition, this is not as RNA
consuming as the original SMART protocol patented by
Clontech, because we do not need to prepare two reactions
(‘‘tester and driver’’) for finding the log-phase of the
SMART–PCR by sacrificing one of the two reactions for
agarose gel electrophoresis. Accordingly, there is no need
of a subsequent cycling of the second reaction to the
optimal number of cycles, which further reduces the time
spent performing the protocol.
In order to demonstrate the reproducibility of our array
hybridization method, we performed duplicate analyses of
four cases. We could show a high reproducibility with only
6.9% (between 2.2% and 13%) of all spots above a certain
threshold ‘‘falsely’’ indicating regulation. Similarly, Wang et al
(2001) analyzed the relation between hybridization signal
quality (i.e., signal/background ratio) and the consistency of
Table II. Variables selected by univariate analysis
Accession Gene
Average expression value
F-valueNevi Melanoma Metastases
AA292995 Tyrosinase related protein 2 46 127 184 7.2
AA448301 Translation initiation factor 2g 5.5 13.8 5.5 5.7
AA487197 Ubiquitine conjugating enzyme E2I 17 29 66 2.9
AA030013 EST 29 54 99 2.7
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array results. Depending on the quality of the hybridization
signals they found up to 10% of low-quality hybridization
signals, which is comparable with our data. The quality of
array hybridization is influenced by many factors: printing of
arrays, hybridization conditions, RNA quality, and RNA
quantity. The last two are probably the most important
factors for our experimental system, as the amount of RNA
prepared from microdissected tissue is very limited and the
material is exposed to conditions, which might be not
optimal for RNA stability (e.g., hematoxylin and eosin
staining).
Although we control the amplification process by
incorporation of SYBR Green, some amplification-born
changes in the representation of single transcripts are
possible and may affect the reproducibility (Becker et al,
2001).
Taken together, in this transcriptome profiling we found
mainly genes, which were induced with increasing stage of
malignancy. In the stringently filtered data we found four
genes, which showed a reduction of expression by a factor
of 2 from nevi to metastases and a further eight genes,
which were downregulated from melanoma towards
metastases. But this regulation turned out to be not
significant. Genes that were downregulated from nevi
versus melanoma might be underrepresented, because
we included only those genes in the statistical analysis that
exhibited a normalized expression ratio of 5% averaged
over all cases. This strategy ensures that the remaining
genes are more robust candidates. Using a threshold lower
than 5% would lead to more genes entering the analysis but
also to the excess of false positives.
The average expression value of the four genes with the
highest F-values in the univariate analysis of the array
expression data within each class of melanocytic lesion was
calculated (Table III).
The average expression level of Trp2 is induced in later
stages of progression in our set of cases (Table I: nos 1–22).
Interestingly, Trp2 has been found to be involved in the
protection of melanoma cells against apoptosis (Nishioka
et al, 1999). In addition, it was detected to be abundantly
expressed in glioblastoma lesions also deriving from cells of
Table III. Classiﬁcation results based on a multivariate analysis of: (A) array dataa according to the genes with the highest F-values
(Table II), and (B) reverse transcription–PCR datab according to the expression values of eIF2c, UBE2I, and one EST (Table II)
Class Total
Predicted classiﬁcation
Nevus MM Metastases
(A)
Number Nevus 9 8 1 0
MM 8 2 6 0
Meta 5 1 0 4
% Nevus 100 88.9 11.1 0
MM 100 25 75 0
Meta 100 20 0 80
(B)
Number Nevus 3 2 1 0
MM 5 0 5 0
Meta 5 0 1 4
% Nevus 100 66.7 33.3 0
MM 100 0 100 0
Meta 100 0 20 80
a81.8% of all cases were classified correctly.
b84.6% of all cases were classified correctly.
Figure 3
Statistical clustering by canonical discriminance analysis. The first
and second function discriminance values for each case are plotted.
Nevi: red spots; melanoma: green triangles; metastasis: blue squares.
The center of each cluster is marked by an open square in the
appropriate color.
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neuroectodermal offspring (Udono et al, 2001). As cancer
cells are much more resistant against apoptosis than their
untransformed counterparts, this might be a further me-
chanism switched on during melanoma progression. On the
other hand, Orlow et al (1998), compared the expression of
Trp2 in melanoma and melanoma metastases in a syngenic
mouse model and found a trend of downregulation of Trp2 in
lesions of more aggressive local growth. At later stages of
progression melanoma lesions tend to become amelanotic
and, therefore, one could expect that the expression of
some of the genes of the melanogenesis pathway are lost or
downregulated (Orlow et al, 1995). Even if melanin produc-
tion is impaired, however, some of the pigment genes are still
expressed varying from case to case (Sarantou et al, 1997).
eIF2g is a subunit of the eukaryotic translation initiation
factor 2 (eIF2), which is a heterotrimeric G-protein required
for GTP-dependent delivery of initiator tRNA to the ribosome.
The eIF2g seems to be transiently upregulated in melanomas
in comparison with nevi and metastasis. Erickson and
Hannig (1996) showed that a mutation in the eIF2g gene
leads to reduced growth rates. In addition they demon-
strated that eIF2g is involved in overriding the lethal effect of
the tumor suppressor gene PKR (Erickson et al, 2001). These
data suggest, that eIF2g may be involved in an important
phase of developing autonomous melanoma growth.
Our observation of UBE2I being progressively upregu-
lated (neviomelanomaometastases) underscores a pos-
sible influence of disrupted ubiquitine pathways in
melanomas: Ubiquitinylation and subsequent degradation
of the ubiquitinylated proteins by the proteasome machinery
accounts for the regulation of proteins, such as cyclins,
cyclin-dependent kinase inhibitors, p53, c-Jun and c-Fos
(Ciechanover et al, 2000). Loss of the fine-tuned regulation
of the G1/S transition during the cell cycle is assumed to be
an important part of melanoma progression (Kamb et al,
1994; Vogt et al, 1999; Bataille, 2000). Therefore, our
observation adds a new and possibly important aspect of
modulating G1/S control in certain melanoma subsets.
Seufert et al (1995) showed a direct involvement of UBE2I
in cell cycle progression via interaction with cyclins.
Taken together, our data show, that the melanoma
progression markers selected in this study for diagnostic
and classification purposes, may also have a significant
biologic role in melanoma progression, which needs further
experimental evaluation.
Using the four genes described above, we were able to
discriminate between nevi, melanomas, and melanoma
metastases in 82% of all cases. One nevus was classified
as a melanoma and two melanomas as nevi (Table III, Fig 3).
The metastases were included as a control group, even
if there is no molecular biologic method necessary to
differentiate between a lymph node metastasis and a nevus
in the skin.
The potential usefulness of our marker set is further
supported by the TaqMan validation. The expression profile
of the marker genes detected by array analysis (Trp2, eIF2g,
UBE2I, and the EST ) was analyzed by quantitative real-time
reverse transcription–PCR. The TaqMan data classified the
lesions with comparable accuracy (85%). Although this is
not higher than the diagnostic accuracy using standard
techniques, analyzing a higher number of cases based on
the methodology provided in this work will enhance the
quality of marker genes as the number of statistically
significant variables included in the marker profile will grow.
A further conclusion from our data is that by assessing
the number of genes in different functional groups within four
clusters (Fig 2, legend) it becomes evident that most of the
genes are regulated during progression from nevus towards
melanoma (Fig 2). This may indicate that the changes that
occur in early transformation are partly conserved during
further tumor progression. Hence, one can assume that
profiling of the primary melanoma lesions will also disclose
prognostic information in addition to its doubtless diagnostic
value. The combination of LPC together with real-time PCR
amplification of RNA appears to be sufficiently fast and
reliable to become feasible for routine analysis of melano-
Table IV. Mean expression valuesa of genes analysed by Taqman reverse transcription–PCR
Gene Nevi MM Metastases Regulation by array analysesb
SCAMP2c 4.88 3.06 3.44 up
MDA-7 1.48 15.42 1.34 up
Desmin 0.33 1.64 0.61 up
CD68 2.69 6.13 6.43 up
Syntaxinc 3.07 0.47 1.97 up
Proteoglycan 0.81 1.71 1.94 up
HMOX1 1.90 5.01 3.31 up
RNPL 3c 5.58 3.81 6.11 up
UBE2I 4.74 5.57 7.08 up
eIF2g 16.31 11.73 20.69 up
EST 0.99 1.28 1.75 up
Trp2 26.25 49.72 12.07 up
aMean expression ratios normalized to GAPDH.
bTendence of regulation observed by array analyses from nevi towards malignant cases (MM, metastases).
cNo confirmation of regulation between reverse transcription–PCR and array results.
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cytic lesions. Although LPC might not be necessary for
larger melanocytic lesions, it does have advantages as to
the coverage of all, even early, small, incipient lesions in
further academic studies. This could enhance the diagnosis
and eventually the prognostic evaluation of melanocytic
tumors in the future as it has been demonstrated in breast
cancer patients (Ahr et al, 2002).
Materials and Methods
Patients’ material Before surgical treatment a written informed
consent was obtained approved by the ethics committee. Tissue
samples from excised melanocytic lesions, not needed for
dermatopathologic evaluation, were snap frozen immediately after
surgery in liquid nitrogen and stored at 801C (Table I). For laser
microdissection, cryosections (10 mm) were prepared, fixed, and
stained as for routine hematoxylin and eosin staining using RNase-
free conditions and kept on dry ice until LPC.
Laser microbeam microdissection and LPC Collection of
melanocytic cells by LPC was performed as described (Westphal
et al, 2002). From all lesions, nests containing melanocytic cells
were excised. Before catapulting, contaminating cells (e.g., infiltrat-
ing lymphocytes) were eliminated by laser ablation. A minimum of
200 cell equivalents (about 1000 visible cells) were harvested. The
nests were taken from the complete tumor region to obtain a
representative selection of the given tumor.
Isolation of total RNA The tissue obtained by LPC was lyzed in
50 mL RNA lysis buffer (Gentra Purescript RNA isolation kit, Gentra
Systems, Minneapolis, Minnesota). RNA was isolated according to
the protocol provided by the supplier and resuspended in 12 mL of
RNase-free H2O.
Generation of radioactive probes for array hybridization Re-
verse transcription of the RNA, amplification of the cDNA and
radioactive labeling of the cDNA was performed as described
(Becker et al, 2001) with the following modifications: we now
employed for the SMART amplification step as real-time controlled
approach by using the Rotorgene real-time PCR machine (Corbett
Research, Mortlake, NSW, Australia). The single-strand (ss) cDNA
synthesis was performed according to the SMART-amplification
protocol (Clontech, Heidelberg, Germany). The single-stranded
cDNA was diluted with 40 mL of nuclease-free H2O bidest and
treated for 7 min at 721C to denature the remaining RNA. Twenty
microliters of the diluted ss cDNA was added as a template to the
real-time amplification reaction containing 54 mL of H2O, 10 mL of
0.5  SYBR Green I (no. S-7563, Molecular Probes Inc., Eugene,
Oregon), 10 mL of 10  Advantage PCR reaction buffer, 2 mL of
deoxyribonucleoside triphosphate (10 mM), 2 mL of CDS primer, 2
mL of 50  Advantage polymerase mix (no. 8417-1, Clontech).
During the PCR, the accumulation of the PCR products was
monitored by measuring the intercalation of SYBR Green I into the
DNA (Fig 1) in order to avoid normalization artifacts caused by
overamplification. When the turning points of the logarithmic phase
of the PCR reaction was reached (e.g., cycle 22 and 25, Fig 1a ‘‘A’’
and Fig 1 ‘‘B’’, respectively) the reaction was stopped. Figure 1(a)
shows the complete PCR amplification protocol of a typical
experiment and the quality of the double-stranded cDNA synthe-
sized after 22 (Fig 1a insert: lane A) and 25 cycles (Fig 1a insert:
lane B) in an agarose gel. Equal volumes of the two separate PCR
reactions were loaded. The DNA smears in both lanes show that
the amount and size of the amplified double-stranded cDNA were
comparable. The double-stranded cDNA was purified with the
Qiagen PCR purification kit (Qiagen, Hilden, Germany) and 100 ng
was labeled radioactively with a33P-deoxycytidine triphosphate by
standard random primed Klenow fragment synthesis.
Quantitative PCR For validation of the data obtained by array
analyses the cDNA was subjected to quantitative real-time PCR
using specific FAM labeled TaqMan probes (Applied Biosystems,
Foster City, California) for detecting the following genes: tyrosi-
nase-related protein 2 (AA292995), translation initiation factor 2g
(AA448301), ubiquitine conjugating enzyme E2I (AA487197), and
one expressed sequence tag (EST; AA030013). SCAMP2 (R32802),
MDA-7 (AA281635), desmin (AA521431), CD68 (AA421296),
syntaxin 5A (AA452374), proteoglycan 1 (AA278759), heme
oxygenase (T71757), and RNA binding protein (AA054287). As a
control for normalization of the PCR results a specific VIC labeled
GAPDH probe was included in each reaction (no. 4310884E,
Applied Biosystems). The PCR reaction was set up as recom-
mended by the supplier.
Array hybridization and analysis The cDNA arrays (human
GeneFilters no.GF200 no.1, Research Genetics, Huntsville,
Alabama) were hybridized as described (Becker et al, 2001).
The hybridized membranes were exposed 36 h on a mounted
phosphoimager screen (Amersham-Pharmacia Biotech, Freiburg,
Germany). Data were acquired using the STORM 860 phosphoi-
mager (Amersham-Pharmacia Biotech) and analyzed by the AIDA
array analysis software package (Raytest, Berlin, Germany). Data
were normalized by genomic spots included in every subgrid on
the arrays. For a pairwise comparison of the normalized expression
data an appropriate expression threshold (see below) was set in
the AIDA comparison module. Genes below this threshold were not
taken into account (Fig 1b: yellow spots). As demonstrated earlier,
genes regulated at least by a factor of 3 can be considered as truly
regulated with very few exceptions (Becker et al, 2001). Figure 1(b)
shows an example displayed by the AIDA comparison module,
where 3-fold downregulated genes are located below the green
line and 3-fold upregulated genes above the red line in the array
comparison view. The genes between both lines (Fig 1b: blue
spots) are considered as nonregulated.
Statistical analysis of array data Genes reaching a minimum
normalized expression ratio of at least 5% of the averaged signal
over all cases were included in the statistical analysis. The
statistical analysis of the filtered data was performed with the
SPSS software (SPSS Inc., Chicago, Illinois). The most significant
features in univariate analysis were used for a multivariate,
stepwise discriminance analysis in order to discriminate nevi,
melanomas, and melanoma metastases.
Functional clustering of genes For the genes passing the
threshold defined above the averaged normalized expression ratio
for each class of melanocytic lesions was calculated separately.
The genes with ‘‘known function’’, in accordance with the gene
information available in the OMIM database (http://www.ncbi.
nlm.nih.gov), were sorted into functional groups ‘‘metabolism’’,
‘‘signaling and cell cycle’’, ‘‘receptors and attachment’’, ‘‘others
with known function’’; those with no functional characterization
were grouped as ‘‘unclassified’’. For each gene the pattern of
regulation, i.e., upregulation or downregulation in nevi versus
melanomas versus metastases, was determined as follows: (1)
genes upregulated from nevi to melanomas; (2) genes upregulated
from melanomas towards metastases; (3) genes upregulated from
nevi to melanomas and further upregulated in metastases; and
(4) upregulated from nevi to melanomas and downregulation
in metastases. The number of genes for each pattern within its
functional group was counted.
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